A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).

Trial Details

NCT ID
NCT06988488
Phase
PHASE1 / PHASE2
Sponsor
Celgene
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Elranatamab
  • Mezigdomide
  • Dexamethasone
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Hackensack, New Jersey, United States|40.88593,-74.04347
  • Houston, Texas, United States|29.76328,-95.36327
  • Calgary, Alberta, Canada|51.05011,-114.08529

Key Eligibility Criteria

  • Age ≥18 with history of relapsed and refractory multiple myeloma (RRMM) treated with 2 to 4 prior lines of anti-myeloma therapy (Phase 1) or 1 to 3…
  • Measurable MM by local laboratory.
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.
  • Adherence to contraception requirements.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →